Panacea Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Panacea Pharma
Largest movements
No asset line moved by more than 1% of the balance sheet total.
- Reserves +€63,348
up €63,348 (+7.1%), from €895,489 to €958,837
of which Distributable reserves: +€63,348
- Debts after one year -€34,546
down €34,546 (-6.4%), from €539,981 to €505,435
- Other debts -€28,427
down €28,427 (-96.1%), from €29,571 to €1,144
- Financial income -€93,696
down €93,696 (-98.7%), from €94,933 to €1,237
- Gross operating margin +€45,221
up €45,221 (+67.8%), from €66,727 to €111,948
- Taxes +€3,887
up €3,887 (+19.5%), from €19,906 to €23,793
- Financial charges -€1,346
down €1,346 (-5.2%), from €26,002 to €24,656
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,572,722 | €1,565,508 | -€7,214 | -0.5% |
| Fixed assets | 21/28 | €1,485,600 | €1,485,600 | = | 0.0% |
| Financial fixed assets | 28 | €1,485,600 | €1,485,600 | = | 0.0% |
| Current assets | 29/58 | €87,122 | €79,908 | -€7,214 | -8.3% |
| Current investments | 50/53 | €50,000 | €50,864 | +€864 | +1.7% |
| Cash at bank and in hand | 54/58 | €36,906 | €29,044 | -€7,862 | -21.3% |
| Deferred charges and accrued income | 490/1 | €216 | €0 | -€216 | -100% |
| Total equity and liabilities | 10/49 | €1,572,722 | €1,565,508 | -€7,214 | -0.5% |
| Equity | 10/15 | €945,489 | €1,008,837 | +€63,348 | +6.7% |
| Contributions | 10/11 | €50,000 | €50,000 | = | 0.0% |
| Reserves | 13 | €895,489 | €958,837 | +€63,348 | +7.1% |
| Non-distributable reserves | 130/1 | €0 | - | = | |
| Reserves not available under the articles | 1311 | €0 | - | = | |
| Distributable reserves | 133 | €895,489 | €958,837 | +€63,348 | +7.1% |
| Profit (loss) carried forward | 14 | €0 | €0 | = | |
| Amounts payable | 17/49 | €627,233 | €556,672 | -€70,562 | -11.2% |
| Amounts payable after more than one year | 17 | €539,981 | €505,435 | -€34,546 | -6.4% |
| Financial debts | 170/4 | €539,981 | €505,435 | -€34,546 | -6.4% |
| Amounts payable within one year | 42/48 | €87,253 | €51,237 | -€36,016 | -41.3% |
| Current portion of amounts payable after more than one year | 42 | €33,170 | €34,546 | +€1,376 | +4.1% |
| Trade debts | 44 | €1,279 | €478 | -€801 | -62.6% |
| Suppliers | 440/4 | €1,279 | €478 | -€801 | -62.6% |
| Taxes, remuneration and social security | 45 | €23,233 | €15,069 | -€8,164 | -35.1% |
| Taxes | 450/3 | €23,233 | €15,069 | -€8,164 | -35.1% |
| Other amounts payable | 47/48 | €29,571 | €1,144 | -€28,427 | -96.1% |
| Accrued charges and deferred income | 492/3 | €0 | - | = | |
| Other operating charges | 640/8 | €1,467 | €1,389 | -€78 | -5.3% |
| Gross operating margin | 9900 | €66,727 | €111,948 | +€45,221 | +67.8% |
| Operating profit (loss) | 9901 | €65,260 | €110,559 | +€45,299 | +69.4% |
| Financial income | 75/76B | €94,933 | €1,237 | -€93,696 | -98.7% |
| Recurring financial income | 75 | €94,933 | €1,237 | -€93,696 | -98.7% |
| Financial charges | 65/66B | €26,002 | €24,656 | -€1,346 | -5.2% |
| Recurring financial charges | 65 | €26,002 | €24,656 | -€1,346 | -5.2% |
| Profit (loss) for the period before taxes | 9903 | €134,191 | €87,140 | -€47,051 | -35.1% |
| Income taxes | 67/77 | €19,906 | €23,793 | +€3,887 | +19.5% |
| Profit (loss) for the period | 9904 | €114,285 | €63,348 | -€50,938 | -44.6% |
| Profit (loss) for the period to be appropriated | 9905 | €114,285 | €63,348 | -€50,938 | -44.6% |
Source: filed annual accounts (NBB), financial years ended 30 June 2024 and 30 June 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 October 2026 via checked.be.